Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant ZIKV E antibody

ZIKV E Reactivity: Zika Virus (ZIKV) Func Host: Human Monoclonal ZKA64 unconjugated Recombinant Antibody
Catalog No. ABIN6253501
  • Target See all ZIKV E products
    ZIKV E (Zika Virus Envelope (ZIKV E))
    Antibody Type
    Recombinant Antibody
    Reactivity
    • 6
    • 1
    Zika Virus (ZIKV)
    Host
    • 4
    • 3
    Human
    Clonality
    • 6
    • 1
    Monoclonal
    Conjugate
    • 7
    This ZIKV E antibody is un-conjugated
    Application
    • 6
    • 2
    • 1
    Functional Studies (Func)
    Purpose
    anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)
    Characteristics
    Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.
    Purity
    >95 % (SDS-PAGE)
    Endotoxin Level
    <0.001EU/μg
    Immunogen
    Zika Virus
    Clone
    ZKA64
    Isotype
    IgG1 kappa
  • Application Notes
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    Lot specific
    Buffer
    Liquid. In PBS.
    Preservative
    Without preservative
    Handling Advice
    Avoid freeze/thaw cycles.
    Storage
    4 °C,-20 °C
    Storage Comment

    Short Term Storage: +4°C

    Long Term Storage: -20°C

    Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.

  • Target
    ZIKV E (Zika Virus Envelope (ZIKV E))
    Alternative Name
    Zika Virus Envelope Protein (ZIKV E Products)
    Target Type
    Viral Protein
    Background

    Alternate Names/Synonyms: ZIKV E Protein

    Product Description: The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.

You are here:
Support